Editor's note

This ExpertREACT article was originally published on 23 October 2008. Deal terms, pipeline positions and commercial assessments described reflect the state of knowledge at that date.

The AFFiRiS acquisition: a therapeutic pivot

GSK Biologicals announced that it had acquired exclusive rights to the beta-amyloid vaccine programmes of AFFiRiS GmbH, a Vienna-based biotechnology company founded in 2003 with management connections to Intercell AG. The deal involved an upfront payment of £17.5m, with AFFiRiS eligible to receive further milestone payments totalling £334m if programmes were developed successfully. AFFiRiS' programmes were based on the AFFiTOPE technology - a platform designed to induce a relevant immune response by mimicking "self" antigens without inducing pathological auto-immunity. For Alzheimer's disease, where abnormal beta-amyloid protein accumulation is a central feature of pathogenesis, an immunological approach using AFFiTOPE peptides in Phase I clinical development aimed to generate antibodies clearing pathological amyloid deposits.

Large vaccine companies had historically focused on prophylactic vaccines preventing infectious diseases with established immune correlates of protection. The move into Alzheimer's - a chronic, age-related neurodegenerative condition with enormous unmet need and no disease-modifying treatments - represented a genuine expansion of GSK's vaccine ambitions. The commercial potential was enormous: Alzheimer's affects millions of elderly individuals globally, and any vaccine with proven clinical benefit in even a subset of patients could command premium pricing. The risk was correspondingly high given the track record of Alzheimer's drug development failures.

AFFiRiS deal: potential total payments
£334m
Maximum milestone payments to AFFiRiS if programmes are successfully developed; £17.5m paid upfront to acquire exclusive rights to AFFiTOPE Alzheimer's programmes

A signal of broader therapeutic vaccine ambitions

VacZine Analytics interpreted the AFFiRiS deal as a signal that major vaccine companies - led by GSK - were increasingly willing to consider therapeutic applications of vaccine technology for non-communicable chronic diseases. GSK was already building therapeutic pipeline candidates through its MAGE-A3 ASCI cancer immunotherapy programme and had committed significantly to the MPL/AS adjuvant platform through Corixa. The AFFiTOPE platform also had potential applications beyond Alzheimer's - including cardiovascular and other neurodegenerative conditions - suggesting GSK was acquiring a technology rather than just a single product. Whether or not the specific Alzheimer's programme succeeded, VacZine Analytics believed the deal marked the beginning of a more deliberate expansion of the therapeutic vaccine concept by established players.